NightstaRx

NightstaRx

NightstaRx

Nightstar is biopharmaceutical company, focused on developing gene therapies for retinal dystrophies. Our mission is to maintain and restore sight in patients.
Type
B2b
Founded
2013
Raised
$174.6M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$75,000,000
Post-IPO equity - 2017
$45,000,000
Venture capital (Series C) - 2017
Redmile Group Wellington Management Syncona Partners +1
Team Size
1–10
Employees
$45,000,000 Venture capital (Series C)
biospace , Biotech 365

Eye Gene Therapy Firm NightstaRx Nabs Another 45 Million